Already competing to bring the first vaccine against respiratory syncytial ... three clinical trials while it investigates a safety signal. Pfizer's phase 3 MATISSE study of RSVpreF as a maternal ...

Pfizer’s Digital Innovation Lab recently sponsored a Vaccines Global Innovation Challenge and provided four finalists with a worldwide audience to pitch to at the Frontiers Health conference on ...

Its rival Moderna said earlier this month, however, that it has already fully enrolled a 6,000-subject phase 3 study of its quadrivalent vaccine candidate mRNA-1010 in the southern hemisphere ...

Pfizer's vaccine for Clostridium difficile (C. diff) looks like it may join a growing list of candidates that have been shelved or delayed, after the shot failed to meet its primary objective in a ...

GlaxoSmithKline has found a replacement for head of vaccines R&D Emmanuel Hanon, who left the company for a US biotech earlier this year, hiring Phil Dormitzer from ...

Few companies embody the term 'pharma giant' as much as Pfizer. Here we take a look at ... one of the first in the world to get a COVID-19 vaccine approved – via its collaboration with BioNTech ...

Pfizer Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services, Scrap for the year ending 31-Mar-2024.For the quarter ended 31-12-2024, the company has reported a Standalone Total ...

The acceleration into cancer comes as Pfizer is facing a sharp contraction in the market for COVID-19 vaccines, which have underpinned growth in the last few years - one of the drivers for the ...

Pre-market: 4:24:23 am GMT-5 ...

After hours: 7:59:36 pm GMT-5 ...

The study reviewed available evidence on safety and efficacy of statin therapy ... effects occur in 18-20% of people. An independent BMJ review later found the articles did not reflect caveats ...